vorinostat has been researched along with enfuvirtide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cardillo, TM; Chang, CH; Falkeborn, T; Goldenberg, DM; Hinkula, J; Li, R; Loo, M; Rossi, EA; Wahren, B | 1 |
1 review(s) available for vorinostat and enfuvirtide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for vorinostat and enfuvirtide
| Article | Year |
|---|---|
A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.
Topics: Amino Acid Sequence; Animals; Anti-HIV Agents; Drug Design; Drug Stability; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV-1; Humans; Hydroxamic Acids; Immunoglobulin G; Jurkat Cells; Mice; Molecular Sequence Data; Neutralization Tests; Peptide Fragments; Virus Activation; Virus Internalization; Virus Replication; Vorinostat | 2012 |